The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy

REFERENCES

• Palella FJ, Delaney KM, Moorman AC, et al. Declining mor-tality and morbidity in HIV-infected ambulatory patients. New Eng' J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; October 10,2006. Available at: http://AIDSinfo.nih.gov.
   Google Scholar
• Palella FJ, Moorman AC, Chmiel J, Chan C, Holmberg SD, HIV Outpatient Study Investigators. Durability and predic-tors of success of highly active antiretroviral therapy (ART) for ambulatory HIV-infected patients. AIDS. 200216: 1617–1627.
   Google Scholar
• Heath K, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 200115: 231–239.
   Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of periph-eral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS. 1998;12: F51–58.
   PubMed Web of Science ®Google Scholar
• Carr A, Hudson J, Chau J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: randomised, controlled, open-label multi-centre study. AIDS. 200115: 1811–1822.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Ringland C, et al. Reversibility of li-poatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX exten-sion study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hesssenthaler SM, et al. Im-provement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
   PubMed Web of Science ®Google Scholar
• John M, McKinnon EJ, James IR, et al. Randomized, con-trolled, 48-week study of switching stavudine and/or protease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003;33:29–33.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, ran-domized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipid-emia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33:22–28.
   PubMed Web of Science ®Google Scholar
• Moyle G, Sabin C, Cartledge J, et al. A randomized com-parative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043–2050.
   PubMed Web of Science ®Google Scholar
• Milinkovic A, Lopez S, Vidal S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007;12(3):407–415.
   PubMed Web of Science ®Google Scholar
• Moreno S, Domingo P, Elias MJP, et al. Identification and follow-up of adverse events related to NRTI use that in the clinical practice cause their substitution by tenofovir DF (48 week data from the RECOVER study). Presented at: Third International AIDS Society Conference on HIV Patho-genesis and Treatment; July 24–27, 2005; Rio de Janeiro, Brazil.
   Google Scholar
• Ribera E, Paradineiro JC, Sauleda S, et al. Improvements in subcutaneous fat, lipid profile and parameters of mito-chondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). Presented at: 12th Conference on Retroviruses and Op-portunistic Infections; February 22–25, 2005; Boston, MA.
   Google Scholar
• Carr A, Workman C, Carey D, et al. No effect of rosiglita-zone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363: 429–438.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naive patients: a 3 year randomized trial. JAMA. 2004;292: 191–201.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Saag MS, Schechter M, et al. International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296(7):827–843.
   PubMed Web of Science ®Google Scholar
• Cassetti I, Madruga JVR, Suleiman JMAH, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164–172.
   PubMed Web of Science ®Google Scholar
• National Institutes of Allergy and Infectious Diseases. Divi-sion of AIDS Table of Grading Severity of Adult Adverse Experiences. August 1992. Available at: http://rcc.tech-res-intl.com.
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Levy S, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creati-nine: a new prediction equation. Ann Int Med. 1999;130: 461–470.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, em-tricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. N Enql J Med. 2006;3: 251–260.
   Web of Science ®Google Scholar
• Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16: 1257–1263.
   PubMed Web of Science ®Google Scholar
• Squires K, Pozniak AL, Pierone G, et al. Tenofovir diso-proxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139:313–320.
   PubMed Web of Science ®Google Scholar
• Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir-containing highly active antiretroviral therapy regimens: a cohort and case-control study. J Acquir Im-mune Defic Syndr 2004;37:1489–1495.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared to nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–1197.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Tenofovir and changes in renal function: reply to Gupta [Letter]. Clin Infect Dis. 2005;41:571.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in anti-retroviral-naive patients: virologic, immunologic, and mor-phologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006;43(5):535–540.
   PubMed Web of Science ®Google Scholar
• Gayet-Ageron A, Ananworanich J, Jupimai T, et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother. 2007;59(5)1 034–1037.
   Web of Science ®Google Scholar
• Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement [online]. 2000 March 27–29;17(1): 1–36. Available at: http://consensus.nih.gov/2000/2000Osteoporosis11html.htm
   Google Scholar